Towia Libermann

Biography
Dr. Libermann is an internationally recognized translational investigator with a strong track record in precision medicine, biomarker discovery and translational studies of cancer, neurological and immunological diseases. His lab is focused on applying proteomics approaches to identify proteins that may be exploited as biomarkers or targets for therapeutic intervention, starting with his seminal discovery of EGF receptor gene amplifications in glioblastomas. Dr. Libermann has been at the forefront of next generation proteomics and plays a central role in driving biomarker discovery to the next level. Libermanns group uses the aptamer-based SomaScan proteomics platform to discover and validate diagnostic, predictive, and prognostic biomarkers for various diseases using liquid biopsies such as extracellular vesicles and body fluids. Using the latest in machine learning, Libermanns group has developed predictor models for applications in early detection, disease diagnosis, prediction of therapeutic response, monitoring of disease progression, and outcome prediction.

---

Talk
Accelerating Precision Medicine With Aptamer-Based 11k SomaScan Proteomics
Novel proteomics platforms have been developed to drive precision medicine and biomarker discovery. We will present our efforts on non-invasive and tissue biomarkers for a broad range of clinically highly relevant diagnostic, predictive, and prognostic indications using the currently most comprehensive, high throughput proteomics platform, SomaScan v5.0, measuring 11,000 proteins.

Spatial Showcase:
Harvard Medical School
Beth Israel Deaconess Medical Center in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital and New England Deaconess Hospital.